Albiglutide

Identification

Summary

Albiglutide is a GLP-1 agonist used to manage type 2 diabetes mellitus.

Generic Name

Albiglutide

DrugBank Accession Number

DB09043

Background

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

Type

Biotech

Groups

Approved

Biologic Classification

Protein Based Therapies
Fusion proteins

Protein Structure

Protein Chemical Formula: C₃₂₃₂H₅₀₃₂N₈₆₄O₉₇₉S₄₁
Protein Average Weight: 72970.0 Da

Sequences

> Albiglutide sequence
HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGR
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAE
NCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLP
KLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTK
VHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA
DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKC
CAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVST
PTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTES
LVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKAT
KEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL

Download FASTA Format

Synonyms

Albiglutida
Albiglutide

External IDs

GSK-716155
GSK716155

Pharmacology

Indication

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Type 2 Diabetes Mellitus

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.

Target	Actions	Organism
AGlucagon-like peptide 1 receptor	agonist	Humans

Absorption

Maximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively

Volume of distribution

11 L.

Protein binding

Not Available

Metabolism

Biotransformation studies have not been performed. Because albiglutide is an albumin fusion protein, it likely follows a metabolic pathway similar to native human serum albumin, which is catabolized primarily in the vascular endothelium.

Route of elimination

Not Available

Half-life

4-7 days.

Clearance

67 mL/h.

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

-RISK OF THYROID C-CELL TUMORS -Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Albiglutide.

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Acarbose	The risk or severity of hypoglycemia can be increased when Acarbose is combined with Albiglutide.
Acebutolol	The therapeutic efficacy of Albiglutide can be increased when used in combination with Acebutolol.
Acetazolamide	The therapeutic efficacy of Albiglutide can be increased when used in combination with Acetazolamide.
Acetohexamide	Albiglutide may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazole	The therapeutic efficacy of Albiglutide can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acid	The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Albiglutide.
Alclometasone	The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Albiglutide.
Alogliptin	The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Albiglutide.
Amcinonide	The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Albiglutide.
Aminosalicylic acid	Aminosalicylic acid may increase the hypoglycemic activities of Albiglutide.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Eperzan	Injection, powder, for solution	30 mg	Subcutaneous	Glaxo Smith Kline Trading Services	2021-01-12	2019-02-20
Eperzan	Powder, for solution	30 mg / 0.5 mL	Subcutaneous	Glaxosmithkline Inc	Not applicable	Not applicable
Eperzan	Injection, powder, for solution	50 mg	Subcutaneous	Glaxo Smith Kline Trading Services	2021-01-12	2019-02-20
Eperzan	Injection, powder, for solution	50 mg	Subcutaneous	Glaxo Smith Kline Trading Services	2021-01-12	2019-02-20
Eperzan	Injection, powder, for solution	30 mg	Subcutaneous	Glaxo Smith Kline Trading Services	2021-01-12	2019-02-20
Eperzan	Powder, for solution	50 mg / 0.5 mL	Subcutaneous	Glaxosmithkline Inc	Not applicable	Not applicable
Tanzeum	Injection, powder, lyophilized, for solution	30 mg/0.5mL	Subcutaneous	GlaxoSmithKline LLC	2014-04-15	2020-09-30
Tanzeum	Injection, powder, lyophilized, for solution	50 mg/0.5mL	Subcutaneous	GlaxoSmithKline LLC	2014-04-15	2020-08-31

Chemical Identifiers

UNII: 5E7U48495E
CAS number: 782500-75-8

References

General References

Trujillo JM, Nuffer W: Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov;48(11):1494-501. doi: 10.1177/1060028014545807. Epub 2014 Aug 18. [Article]

External Links

KEGG Drug: D08843
PubChem Substance: 347910396
RxNav: 1534763
Wikipedia: Albiglutide

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Diabetes Mellitus	1
4	Completed	Treatment	Type 2 Diabetes Mellitus	1
4	Terminated	Treatment	Diabetes Mellitus	1
4	Terminated	Treatment	Type 2 Diabetes Mellitus	2
3	Completed	Treatment	Diabetes Mellitus	1
3	Completed	Treatment	Type 2 Diabetes Mellitus	12
3	Withdrawn	Treatment	Type 2 Diabetes Mellitus	2
2	Completed	Basic Science	Congestive Heart Failure (CHF)	1
2	Completed	Treatment	Type 1 Diabetes Mellitus	1
2	Completed	Treatment	Type 2 Diabetes Mellitus	5

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, powder, for solution	Subcutaneous	30 MG
Injection, powder, for solution	Subcutaneous	50 MG
Powder, for solution	Subcutaneous	30 mg / 0.5 mL
Powder, for solution	Subcutaneous	50 mg / 0.5 mL
Injection, powder, lyophilized, for solution	Subcutaneous	30 mg/0.5mL
Injection, powder, lyophilized, for solution	Subcutaneous	50 mg/0.5mL

Prices

Not Available

Patents

Not Available

Properties

State: Solid
Experimental Properties: Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Glucagon-like peptide 1 receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Transmembrane signaling receptor activity
Specific Function: This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name: GLP1R
Uniprot ID: P43220
Uniprot Name: Glucagon-like peptide 1 receptor
Molecular Weight: 53025.22 Da

References

Trujillo JM, Nuffer W: Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov;48(11):1494-501. doi: 10.1177/1060028014545807. Epub 2014 Aug 18. [Article]
Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L: Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017 Jan 13;16(1):6. doi: 10.1186/s12933-016-0490-6. [Article]
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ: Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. [Article]

Drug created at April 28, 2015 21:08 / Updated at May 28, 2022 06:24

Albiglutide

Identification

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Targets

References